Tetrahydrocurcumin Chemosensitizes Breast Cancer to Albumin-Bound Paclitaxel by Enhancing SPARC Expression through Demethylation

Table 2

Relationship between the expression Of SPARC protein and clinical pathology of patients with breast cancer.

		(%)	High (N)	Low (N)
Age (year)	≤40	12 (7.59%)	5	7	0.558
	>40	146 (92.41%)	76	70
Menopausal status	Premenopausal	51 (32.28%)	23	28	0.311
	Postmenopausal	107 (67.72%)	58	49
TNM stage	I-II	124 (78.48%)	66	58	0.439
	III-IV	34 (21.52%)	15	19
Tumor size (cm)	≤2	68 (43.04)	40	28	0.11
	>2	90 (56.96%)	41	49
Lymph node metastasis	No	72 (45.57%)	50	22	<0.0001
	Yes	86 (54.43%)	31	55
Her2+	No	98 (62.03%)	54	44	0.073
	Yes	60 (37.97%)	24	36
ER+	No	89 (56.33%)	42	47	0.265
	Yes	69 (43.67%)	39	30
Triple-negative BC	No	124 (78.48%)	63	61	0.848
	Yes	34 (21.52%)	18	16